TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01844323

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib Formulation Reference
Description: Single 45 mg dose; Dosage form is capsule taken orally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib Formulation Test
Description: Single 45 mg dose; Dosage form is capsule taken orally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib Formulation Test
Description: Single 45 mg dose; Dosage form is capsule taken orally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib Formulation Test
Description: Single 45 mg dose; Dosage form is capsule taken orally.
Study: NCT00659269

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin (MV)
Description: Multivitamins containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12 will be given to the patients on this arm.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin + Vitamin B12 + Vitamin B6
Description: Multivitamin (containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12), plus Vitamin B6 tablets and Vitamin B12 injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Patients are treated per standard of care according to the choice of the treating physician with heavy metals (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), or vinca alkaloids (vincristine, vinorelbine)~Ranges of cumulative doses (in mg/m2) are:~paclitaxel, 700-960; docetaxel, 240-400; vincristine, 8-16; vinorelbine, 360-480; cisplatin, 240-400; oxaliplatin, 400-800; abraxane, 1200-1800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients are treated per standard of care according to the choice of the treating physician with heavy metals (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), or vinca alkaloids (vincristine, vinorelbine)~Ranges of cumulative doses (in mg/m2) are:~paclitaxel, 700-960; docetaxel, 240-400; vincristine, 8-16; vinorelbine, 360-480; cisplatin, 240-400; oxaliplatin, 400-800; abraxane, 1200-1800
Study: NCT04629794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterolateral Lumbar Fusion with Demineralized Bone Fibers
Description: Posterolateral Lumbar Fusion with Demimeralized Bone Fibers
Study: NCT01988493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
Study: NCT02010307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood extraction
Description: 6 ml blood extraction from each patients in all 3 arms of the study
Study: NCT04629794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterolateral Lumbar Fusion with Bone Morphogenic Protein
Description: Posterolateral Lumbar Fusion with Bone Morphogenic Protein
Study: NCT05649384

Intervention type: DIAGNOSTIC_TEST
Intervention: European Society of Cardiology hs-cTnT/I 0 h/1 h algorithm
Description: High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 1 hour later in the emergency department.
Study: NCT05649384

Intervention type: DIAGNOSTIC_TEST
Intervention: European Society of Cardiology hs-cTnT/I 0 h/3 h algorithm
Description: High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 3 hours later in the emergency department.
Study: NCT00320216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).
Study: NCT04501341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC
Description: Autologous bone-marrow mononuclear cells infused to the main blood vessels that supply the pancreas according to the results of previous pancreatic CT-scan, performed by interventional radiologist. The target is to distribute the BM-MNCs equally in all part of the pancreas. Dosage: 1 x 10\^5 - 1 x 10\^6 CD34 cells/kgBW

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous Infusion of UC-MSC
Description: Allogeneic umbilical cord tissue-derived mesenchymal stem cells will be given via intravenous infusion. Dosage: 2 x 10\^6 cells/kgBW, twice, with three months interval
Study: NCT00320216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group will receive placebo medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients in the placebo group will receive placebo medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients in the placebo group will receive placebo medication.
Study: NCT00639158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: 135 mg capsule, daily, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule, daily, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: 40 mg, tablet, daily, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atorvastatin
Description: 40 mg, tablet, daily, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe
Description: 10 mg capsule, daily, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ezetimibe
Description: 10 mg capsule, daily, 12 weeks
Study: NCT02360059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory and Fine-Motor Tests
Description: Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sensory and Fine-Motor Tests
Description: Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.
Study: NCT01741428

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention (INT1)
Description: The course Program at the Feiring Heart Clinic will:~Clinical examination and ergospirometric testing, optimizing both treatment and prophylactic medication. Promoting physical Activity, changes in lifestyle, dietary changes/weight reduction, smoking cessation. In the follow-up period the participants will be contacted and report regularly through a web-based secure program (MedAxess)(such as: Activity-, dietary- and smoking habits). Each participant will have their own Mentor, helping keeping up the motivation. They will also meet regularly at the local doctors Office which reports relevant parameters to the Project (such as weight, BP, Lipoproteins, blood glucose/HbA1C)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention (INT1)
Description: The course Program at the Feiring Heart Clinic will:~Clinical examination and ergospirometric testing, optimizing both treatment and prophylactic medication. Promoting physical Activity, changes in lifestyle, dietary changes/weight reduction, smoking cessation. In the follow-up period the participants will be contacted and report regularly through a web-based secure program (MedAxess)(such as: Activity-, dietary- and smoking habits). Each participant will have their own Mentor, helping keeping up the motivation. They will also meet regularly at the local doctors Office which reports relevant parameters to the Project (such as weight, BP, Lipoproteins, blood glucose/HbA1C)
Study: NCT01581073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
Study: NCT01738490

Intervention type: DEVICE
Group type: OTHER
Intervention: Bone anchored hearing implant

Intervention type: DEVICE
Group type: OTHER
Intervention: Bone anchored hearing implant
Study: NCT04177745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot application
Description: Before PVC was inserted, the researcher applied a hot application to the catheter insertion site (inner surface of the forearm) using a hot pack for one minute.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold application
Description: Before PVC was inserted, the researcher applied a cold application to the catheter insertion site (inner surface of the forearm) using a cold pack for one minute.
Study: NCT00768105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Dose titration of oral suspension to a tolerable dose in 2-3 dose steps. Investigational product given twice daily for eight days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing to match AZD1656
Study: NCT03598673

Intervention type: DRUG
Intervention: The Efficacy and Tolerability of Nebivolol in Nigerians
Description: To determine the effect of Nevibolol on office blood pressure of Blacks residing in Nigeria
Study: NCT04201418

Intervention type: DRUG
Intervention: Patisiran
Description: Patisiran-lipid complex injection, for intravenous use

Intervention type: DRUG
Intervention: Patisiran
Description: Patisiran-lipid complex injection, for intravenous use

Intervention type: DRUG
Intervention: Patisiran
Description: Patisiran-lipid complex injection, for intravenous use
Study: NCT00047554

Intervention type: DRUG
Intervention: Travoprost, 0.004% ophthalmic solution
Study: NCT01544816

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Snack Product
Description: control food product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snack Product
Description: Experimental food product containing ingredient 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snack Product
Description: Experimental food product containing ingredient 2
Study: NCT03173196

Intervention type: DEVICE
Intervention: Non-invasive Multispectral Sonography
Description: We measure both groups wirh the non-invasive multispectral sonography for 3 and for 30 minutes.

Intervention type: DEVICE
Intervention: Non-invasive Multispectral Sonography
Description: We measure both groups wirh the non-invasive multispectral sonography for 3 and for 30 minutes.
Study: NCT03937375

Intervention type: BEHAVIORAL
Intervention: High PEEP
Description: Use of high levels of PEEP combined with recruitment maneuvers and low tidal volume ventilation during general anesthesia

Intervention type: BEHAVIORAL
Intervention: Low PEEP
Description: Use of low levels of PEEP without recruitment maneuvers and low tidal volume ventilation during general anesthesia
Study: NCT01111500

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Donjoy ER brace
Description: Patients will wear an external rotation brace, the Donjoy ER brace, during treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thoraco brachial brace
Description: Patients will wear an internal rotation brace, a thoraco brachial brace, during treatment.
Study: NCT04153409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAT8881
Description: Two 30 mg capsules of LAT8881

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules of placebo
Study: NCT01506245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based behavioral therapy
Description: The intervention consist of a 6-month family-based behavioural therapy either in group (1 session/week, with a dietician and a psychologist) or in individual setting (with a paediatrician or a dietician in alternance 1x/month). Both therapies include exercise training twice per week (60 minutes each). Parents, or at at least the mother, must participate to the behavioral treatment.
Study: NCT03901248

Intervention type: OTHER
Intervention: No Intervention
Description: Observational study

Intervention type: OTHER
Intervention: No Intervention
Description: Observational study

Intervention type: OTHER
Intervention: No Intervention
Description: Observational study
Study: NCT00840970

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-coated Intranasal Splint
Description: placement of non-coated intranasal splint following FESS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinexus Intranasal Splint
Description: placement of Sinexus Intranasal Splint placed following FESS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinexus Intranasal Splint
Description: placement of Sinexus Intranasal Splint placed following FESS
Study: NCT02998294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Volume Monitor(RVM)
Description: The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial respirator
Description: The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
Study: NCT01701375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991
Description: • PD 0332991 will be given orally days 1,2,3
Study: NCT04620317

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: 10 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01, Bifidobacterium lactis BB12, and inulin oligofructose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active ingredients - Maltodextrins
Study: NCT00504829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCP-AtorFen
Description: 40mg atorvastatin combined with 100mg fenofibrate in a tablet for once daily treatment of dyslipidemia and mixed dyslipidemia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: dyslipidemia and mixed dyslipidemia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate
Description: dyslipidemia and mixed dyslipidemia
Study: NCT03465540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 397
Description: AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 397
Description: AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 397
Description: AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 397
Description: AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 397
Description: AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 397
Description: AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 397
Description: AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 397
Description: AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered intravenously (IV) or orally on Days 1, 8, 15, and 22 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered intravenously (IV) or subcutaneously (SC) daily for the first 7 days of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered intravenously (IV) or subcutaneously (SC) daily for the first 7 days of a 28-day cycle.
Study: NCT01771003

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CellAegis' autoRIC™ Device
Description: Patients in the active group will have the autoRIC device (like a blood pressure cuff) inflated and deflated to a pressure of 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CellAegis' autoRIC™ Device
Description: Patients in the active group will have the autoRIC device (like a blood pressure cuff) inflated and deflated to a pressure of 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles
Study: NCT01850160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GROUP A: Valsartan plus Chlorthalidone
Description: Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GROUP B: Valsartan
Description: GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GROUP C: Chlorthalidone
Description: GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
Study: NCT03103867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM augmented pump with PLGS ,
Description: 5 weeks treatment CGM augmented pump with PLGS compared with 5 weeks treatment with insulin pump with CGM , without integration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump with CGM
Description: 5 weeks treatment continuous subcutaneous insulin infusion pump with CGM without data integration,
Study: NCT03789539

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LD Universal Influenza Vaccine Uniflu
Description: low dose Universal Influenza Vaccine Uniflu

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HD Universal Influenza Vaccine Uniflu
Description: High dose Universal Influenza Vaccine Uniflu

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo saline
Study: NCT01877421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg KSL-W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg KSL-W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg KSL-W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg KSL-W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg KSL-W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg KSL-W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg KSL-W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg KSL-W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg KSL-W

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cetylpyridinium chloride (CPC) as an additive, isomalt as a bulk sweetener, peppermint powder for flavoring, sucralose as an intense sweetener, colloidal silicon dioxide is a flow enhancer, magnesium stearate as a process aid, and the proprietary gum base formulation.
Study: NCT04592757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual mirror therapy via VR headset
Description: Participants will perform Activities of Daily Living (ADL) in a virtual environment through a VR headset. The application is based on mirror therapy. Participants will execute certain arm movements with their non-affected arm, while seeing their affected arm perform said movement in the virtual environment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual mirror therapy via VR headset
Description: Participants will perform Activities of Daily Living (ADL) in a virtual environment through a VR headset. The application is based on mirror therapy. Participants will execute certain arm movements with their non-affected arm, while seeing their affected arm perform said movement in the virtual environment.
Study: NCT04289649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-924 LD
Description: Pitavastatin 2 mg / Ezetimibe 10 mg tables

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-924 HD
Description: Pitavastatin 4 mg / Ezetimibe 10 mg tables

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: K-924 LD Placebo
Description: Pitavastain 2 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: K-924 HD Placebo
Description: Pitavastain 4 mg
Study: NCT04812353

Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up of Io-Fix type fixation
Description: Follow-up of patients who underwent a foot- or ankle reconstruction surgery using the Io-Fix system